Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

NAAS Rating: 5.03, Impact Factor: RJIF 5.98 | Free Publication Certificate
updates
NAAS Rating: 5.03 new
Vol. 7, Issue 11 (2018)

Pharmaceutical evaluation of enzymatically produced chitooligosaccharides

Author(s):
G Arunkumar and K Bhanumathi
Abstract:
Chitooligosaccharides (COS) are the depolymerized products of chitosan polymer. COS has valuable medicinal properties and potent than chitosan. In this study, pharmaceutical potential of enzymatically produced COS was analyzed using Total Antioxidant assay, Protein denaturation inhibition assay, Membrane stabilization assay and Nitric oxide (NO) scavenging assay. COS have shown maximum TAA activity of 168.70 ± 0.45 mg/g equivalents of ascorbic acid at concentration of 1000 µg/ml. Protein denaturation inhibition assay of COS revealed 89.97 ± 0.51% activity at 1000 µg/ml concentration and the IC50 value was found to be 175.44 µg/ml. Membrane stabilization assay confirmed the cell membrane protecting ability of COS with 74.03 ± 2.95 % activity at 1000 µg/ml concentration and the EC50 was found to be 560.45 µg/ml. COS have shown highest NO scavenging activity of 63.73 ± 0.57 % at 500 µg/ml with IC50 value of 277.35 µg/ml. Hence, enzymatically produced COS could be used as drug of choice to treat certain protein and cell membrane related diseases and disorders.
Pages: 156-161  |  403 Views  6 Downloads
How to cite this article:
G Arunkumar, K Bhanumathi. Pharmaceutical evaluation of enzymatically produced chitooligosaccharides. Pharma Innovation 2018;7(11):156-161.
The Pharma Innovation Journal